ITI Pharma and Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹217 Cr

Expense Ratio

0.37%

ISIN

INF00XX01BO9

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

11 Nov 2021

About this fund

ITI Pharma and Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by ITI Mutual Fund. This fund has been in existence for 3 years, 3 months and 11 days, having been launched on 11-Nov-21.
As of 21-Feb-25, it has a Net Asset Value (NAV) of ₹16.13, Assets Under Management (AUM) of 216.51 Crores, and an expense ratio of 0.37%.

ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 15.68% since inception.
The fund's asset allocation comprises around 93.44% in equities, 0.00% in debts, and 6.56% in cash & cash equivalents.
You can start investing in ITI Pharma and Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+11.89%

+12.48% (Cat Avg.)

3 Years

+20.19%

+18.71% (Cat Avg.)

Since Inception

+15.68%

— (Cat Avg.)

Portfolio Summaryas of 31st January 2025

Equity	₹202.31 Cr	93.44%
Others	₹14.2 Cr	6.56%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹34.64 Cr	16.00%
Net Receivables / (Payables)	Cash	₹14.2 Cr	6.56%
Lupin Ltd	Equity	₹13.72 Cr	6.34%
Apollo Hospitals Enterprise Ltd	Equity	₹10.89 Cr	5.03%
Divi's Laboratories Ltd	Equity	₹10.59 Cr	4.89%
Suven Pharmaceuticals Ltd	Equity	₹10.56 Cr	4.88%
Aurobindo Pharma Ltd	Equity	₹10.35 Cr	4.78%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹8.78 Cr	4.05%
Torrent Pharmaceuticals Ltd	Equity	₹8.34 Cr	3.85%
Dr Reddy's Laboratories Ltd	Equity	₹7.34 Cr	3.39%
Alkem Laboratories Ltd	Equity	₹6.31 Cr	2.91%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹5.46 Cr	2.52%
Mankind Pharma Ltd	Equity	₹5.23 Cr	2.42%
Granules India Ltd	Equity	₹4.65 Cr	2.15%
Syngene International Ltd	Equity	₹4.07 Cr	1.88%
Neuland Laboratories Limited	Equity	₹4.04 Cr	1.86%
Orchid Pharma Ltd	Equity	₹3.97 Cr	1.84%
Wockhardt Ltd	Equity	₹3.9 Cr	1.80%
HealthCare Global Enterprises Ltd	Equity	₹3.48 Cr	1.61%
Caplin Point Laboratories Ltd	Equity	₹3.06 Cr	1.41%
Fortis Healthcare Ltd	Equity	₹3.06 Cr	1.41%
FDC Ltd	Equity	₹3.03 Cr	1.40%
Sumitomo Chemical India Ltd Ordinary Shares	Equity	₹2.97 Cr	1.37%
Shilpa Medicare Ltd	Equity	₹2.89 Cr	1.34%
Supriya Lifescience Ltd	Equity	₹2.89 Cr	1.33%
Emcure Pharmaceuticals Ltd	Equity	₹2.76 Cr	1.27%
Vijaya Diagnostic Centre Ltd	Equity	₹2.62 Cr	1.21%
Gland Pharma Ltd	Equity	₹2.51 Cr	1.16%
Yatharth Hospital and Trauma Care Services Ltd	Equity	₹2.45 Cr	1.13%
Rainbow Childrens Medicare Ltd	Equity	₹2.29 Cr	1.06%
Cipla Ltd	Equity	₹2.28 Cr	1.05%
OneSource Specialty Pharma Ltd	Equity	₹2.18 Cr	1.01%
GlaxoSmithKline Pharmaceuticals Ltd	Equity	₹2.04 Cr	0.94%
Sequent Scientific Ltd	Equity	₹2.01 Cr	0.93%
Sai Life Sciences Ltd	Equity	₹1.95 Cr	0.90%
Strides Pharma Science Ltd	Equity	₹1.89 Cr	0.87%
SRF Ltd	Equity	₹1.61 Cr	0.74%
Linde India Ltd	Equity	₹1.53 Cr	0.71%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹192.17 Cr	88.76%
Basic Materials	₹4.5 Cr	2.08%
Industrials	₹1.61 Cr	0.74%

Risk & Performance Ratios

Fund Managers

Dhimant Shah

Since December 2022

Rohan Korde

Since November 2021

Additional Scheme Detailsas of 31st January 2025

ISIN

INF00XX01BO9

Expense Ratio

0.37%

Exit Load

1.00%

Fund Size

₹217 Cr

Age

3 years 3 months

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

Nifty Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹27.99 Cr	11.6%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	1.1%	1.0%	₹815.09 Cr	6.3%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹815.09 Cr	4.8%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹41.19 Cr	9.0%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.4%	1.0%	₹216.51 Cr	11.9%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹216.51 Cr	9.8%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.4%	1.0%	₹2652.24 Cr	12.3%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹2652.24 Cr	10.7%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹866.14 Cr	8.2%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹18.92 Cr	8.9%

About the AMC

ITI Mutual Fund

022-66214999

https://www.itimf.com/

Total AUM

₹9,280 Cr

Address

Mumbai, 400013

Other Funds by ITI Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
ITI Focused Equity Fund Direct Growth Very High Risk	0.5%	1.0%	₹482.56 Cr	7.9%
ITI Liquid Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹80.55 Cr	7.1%
ITI Ultra Short Duration Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹317.43 Cr	7.4%
ITI Multi Cap Fund Direct Growth Very High Risk	0.2%	1.0%	₹1312.94 Cr	-0.6%
ITI Value Fund Direct Growth Very High Risk	0.5%	1.0%	₹301.03 Cr	-0.4%
ITI Conservative Hybrid Fund Direct Growth Moderate Risk	0.2%	0.0%	₹14.80 Cr	8.9%
ITI Dynamic Bond Fund Direct Growth Moderate Risk	0.1%	0.0%	₹47.38 Cr	8.1%
ITI Balanced Advantage Fund Direct Growth Moderately High risk	0.5%	1.0%	₹378.30 Cr	4.8%
ITI Small Cap Fund Direct Growth Very High Risk	0.4%	1.0%	₹2253.76 Cr	6.5%
ITI Large Cap Fund Direct Growth Very High Risk	0.5%	1.0%	₹364.35 Cr	1.8%
ITI Banking & PSU Debt Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹30.73 Cr	7.6%
ITI Banking and Financial Services Fund Direct Growth Very High Risk	0.3%	1.0%	₹265.94 Cr	4.3%
ITI Arbitrage Fund Direct Growth Low Risk	0.2%	0.0%	₹43.18 Cr	7.8%
ITI Overnight Fund Direct Growth Low Risk	0.1%	0.0%	₹18.29 Cr	6.5%
ITI Mid Cap Fund Direct Growth Very High Risk	0.1%	1.0%	₹1095.38 Cr	4.8%
ITI Long Term Equity Fund Direct Growth Very High Risk	0.5%	0.0%	₹374.22 Cr	4.5%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.4%	1.0%	₹216.51 Cr	11.9%
ITI Flexi Cap Fund Direct Growth Very High Risk	0.1%	1.0%	₹1200.60 Cr	4.4%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of ITI Pharma and Healthcare Fund Direct Growth?

The NAV of ITI Pharma and Healthcare Fund Direct Growth, as of 21-Feb-2025, is ₹16.13.

What are the returns of ITI Pharma and Healthcare Fund Direct Growth?

The fund has generated 11.89% over the last 1 year and 20.19% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.

What is the portfolio composition of ITI Pharma and Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 93.44% in equities, 0.00% in bonds, and 6.56% in cash and cash equivalents.

Who manages the ITI Pharma and Healthcare Fund Direct Growth?

The fund managers responsible for ITI Pharma and Healthcare Fund Direct Growth are:-

Dhimant Shah
Rohan Korde

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

Fund Overview

Fund Size

₹217 Cr

Expense Ratio

0.37%

ISIN

INF00XX01BO9

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

11 Nov 2021

Risk Level

Your principal amount will be at Very High Risk